14-day Premium Trial Subscription Try For FreeTry Free
Steris (STE) reported earnings 30 days ago. What's next for the stock?
Investors are optimistic about STERIS (STE) on strong segmental growth.
STERIS (STE) competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach.
Heading into fiscal 2024, STERIS (STE) expects many of its fiscal 2023 challenges to abate, including procedure volumes and supply chain constraints.

Why Shares of Steris Are Up Thursday

12:45pm, Thursday, 11'th May 2023
Steris saw revenue rise by 14% year over year in the fourth quarter. The company upgraded guidance for fiscal 2024 revenue and earnings per share.
Steris (STE) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.04 per share a year ago.
DUBLIN, IRELAND, April 24, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 fourth qua
If you're willing to play the long game, they'll put money in your pocket for decades.

Why Steris Stock Was a Flop This Week

06:47pm, Friday, 10'th Feb 2023
A big earnings miss turned investors off, as did reduced guidance.

STERIS plc (STE) Q3 2023 Earnings Call Transcript

03:42pm, Thursday, 09'th Feb 2023
STERIS plc (NYSE:STE ) Q3 2023 Earnings Conference Call February 9, 2023 10:00 AM ET Company Participants Julie Winter - IR Daniel Carestio - President and CEO Michael Tokich - SVP and CFO Conference
Negative foreign currency and the impact of increased supply chain and inflationary costs hurt STERIS (STE) revenues in the fiscal third quarter.
Steris (STE) delivered earnings and revenue surprises of -9.01% and 4.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
DUBLIN, IRELAND, Jan. 25, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 third quart

2 Monster Stocks to Buy Without Any Hesitation

05:10am, Friday, 23'rd Dec 2022
These two companies are prepared to grow regardless of the economy or the stock market's moods.
STERIS (STE) is on track to achieve its stated goal of approximately $50 million of cost synergies in fiscal 2023.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE